EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review

Overview

Journal Clin Case Rep

Date 2025 Jan 9

PMID 39780907

Authors

Qiongqian Li

Tongze Cai

Xiaoming Zheng

Shunrong Zhang

Chanjuan Li

Huang Tang

Zhiyong Yu

Jianlong Zhou

Affiliations

Soon will be listed here.

Abstract

We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.

References

Salido M, Pijuan L, Martinez-Aviles L, Galvan A, Canadas I, Rovira A . Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2010; 6(1):21-7. PMC: 3359090. DOI: 10.1097/JTO.0b013e3181fb7cd6. View

Shreenivas A, Janku F, Gouda M, Chen H, George B, Kato S . ALK fusions in the pan-cancer setting: another tumor-agnostic target?. NPJ Precis Oncol. 2023; 7(1):101. PMC: 10542332. DOI: 10.1038/s41698-023-00449-x. View

Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X . ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open. 2022; 12(9):e060782. PMC: 9486327. DOI: 10.1136/bmjopen-2022-060782. View

Chuang C, Chen H, Chang H, Tsai Y, Wu K, Chen I . Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers (Basel). 2021; 13(8). PMC: 8072703. DOI: 10.3390/cancers13081966. View

Stewart C, Ralyea C, Lockwood S . Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019; 35(2):151-156. DOI: 10.1016/j.soncn.2019.02.001. View

Pejovic T, Pande N, Mori M, Mhawech-Fauceglia P, Harrington C, Mongoue-Tchokote S . Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Transl Oncol. 2009; 2(4):341-9. PMC: 2781076. DOI: 10.1593/tlo.09199. View

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G . Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019; 12(1):28. PMC: 6436208. DOI: 10.1186/s13048-019-0503-7. View

Jafarian A, Jafaripour M, Gharib M, Salehi M, Roshan N, Etemad S . Molecular Status of Mutation in Epithelial Ovarian Cancer: An Analysis of 57 Cases in the Northeast of Iran. Iran J Pathol. 2023; 18(2):134-139. PMC: 10439751. DOI: 10.30699/IJP.2023.554750.2907. View

Tang S, Yang F, Du X, Lu Y, Zhang L, Zhou X . Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement. Int J Gynecol Pathol. 2016; 35(4):337-47. DOI: 10.1097/PGP.0000000000000260. View

10.

Zheng B, Jiang H, Yang W, Li Y, Liang B, Zhu J . A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer. Cancer Med. 2023; 12(15):15983-15997. PMC: 10469807. DOI: 10.1002/cam4.6241. View

11.

Sandercock J, Parmar M, Torri V . First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer. 1998; 78(11):1471-8. PMC: 2063206. DOI: 10.1038/bjc.1998.709. View

12.

Sun T, Hu Y, He W, Shang Y, Yang X, Gong L . SRT2183 impairs ovarian cancer by facilitating autophagy. Aging (Albany NY). 2020; 12(23):24208-24218. PMC: 7762476. DOI: 10.18632/aging.104126. View

13.

Xiao L, Tang J, Li W, Xu X, Zhang H . Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review. J Ovarian Res. 2020; 13(1):141. PMC: 7702710. DOI: 10.1186/s13048-020-00744-2. View

14.

Schoppmann S, Streubel B, Birner P . Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. Eur J Cancer. 2013; 49(8):1876-81. DOI: 10.1016/j.ejca.2013.02.005. View

15.

Ren H, Tan Z, Zhu X, Crosby K, Haack H, Ren J . Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res. 2012; 72(13):3312-23. DOI: 10.1158/0008-5472.CAN-11-3931. View

16.

Hui B, Zhang J, Shi X, Xing F, Shao Y, Wang Y . EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer. Jpn J Clin Oncol. 2020; 50(12):1470-1474. DOI: 10.1093/jjco/hyaa156. View

17.

Thomas N, Myall N, Sun F, Patil T, Mushtaq R, Yu C . Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2021; 17(1):116-129. DOI: 10.1016/j.jtho.2021.08.009. View

18.

Matsumoto T, Oda Y, Hasegawa Y, Hashimura M, Oguri Y, Inoue H . Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma. Am J Pathol. 2021; 191(10):1837-1850. DOI: 10.1016/j.ajpath.2021.06.009. View

19.

Costa D, Kobayashi S, Pandya S, Yeo W, Shen Z, Tan W . CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29(15):e443-5. DOI: 10.1200/JCO.2010.34.1313. View

20.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S . and mutation status associates with and expression in ovarian cancer. Oncotarget. 2018; 9(25):17501-17511. PMC: 5915132. DOI: 10.18632/oncotarget.24770. View